Evelo Biosciences Inc EVLO

NAS: EVLO | ISIN: US2997341035   29/04/2025
0,001 USD (0,00%)
(0,00%)   29/04/2025

6 november 2023 · Thinking about buying stock in Aldeyra Therapeutics, Alphabet Inc., DraftKings, Evelo Biosciences, or Enlivex Therapeutics? · Persbericht

16 mei 2023 · Flagship Pioneering Launches Metaphore Biotechnologies to Unlock the Therapeutic Potential of Biomimicry · Persbericht

11 januari 2023 · Horizon Technology Finance Provides Fourth Quarter 2022 Portfolio Update · Persbericht

28 februari 2022 · Alltrna Appoints Rare Disease Clinical Research Expert, Dr. Anne Pariser, as Vice President, Medical and Regulatory Affairs · Persbericht

15 februari 2022 · Invaio Sciences Strengthens Its Board Of Directors With The Appointment Of Hugh Grant · Persbericht

13 oktober 2021 · Invaio Sciences Secures $50 Million Debt Financing to Develop and Commercialize Agricultural Solutions to Address Climate Change · Persbericht

25 mei 2021 · Invaio Sciences Raises $88.9 Million to Accelerate the Transition to Biological Agriculture · Persbericht

19 mei 2021 · Invaio Sciences Announces Key Agreement with Fundecitrus in Brazil to Combat Against Citrus Greening · Persbericht

30 maart 2021 · Invaio Sciences Strengthens Leadership Team with Appointment of Peleg Chevion as President and Chief Commercial Officer · Persbericht

9 maart 2021 · Evelo Biosciences Announces Fourth Quarter and Full Year 2020 Financial Results and Business Highlights · Persbericht

2 maart 2021 · Evelo Biosciences to Report Fourth Quarter and Full Year 2020 Financial Results on Tuesday, March 9, 2021 · Persbericht

29 januari 2021 · Evelo Biosciences Announces Pricing of Public Offering of Common Stock · Persbericht

28 januari 2021 · Evelo Biosciences Announces Proposed Public Offering of Common Stock · Persbericht

20 januari 2021 · Evelo Biosciences Reports New Positive Confirmatory Data from Phase 1b Trial of EDP1815 in Atopic Dermatitis · Persbericht

7 januari 2021 · Evelo Biosciences Expands Clinical Programs and Provides 2021 Guidance on Key Milestones · Persbericht

Mijn selecties